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Abstract: A total of 507 strains of the Enterobacteriaceae family were tested for the 
production of ESBL using mini API, ATB Expert system as a screening method, as well as 
the double disk method and E-test for confirmation. The prevalence of ESBL producing E. 
coli is 5.95%, Klebsiella spp. strains 37.7%. All ESBL- producing isolates are susceptible to 
imipenem and clavulanate. The susceptibility to other antimicrobials varies from 36 to 92%. 
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Introduction 
The introduction of antimicrobial agents in clinical practice has greatly contributed to 
improvements in health. Antimicrobial agents have been introduced for decades to treat and 
prevent infectious diseases and infections. However, their use has been accompanied by an 
increasing prevalence of microorganisms that have acquired resistance to one or more of these 
agents, the so-called “antimicrobial resistance”, which has become one of the most urgent 
problems in medicine nowadays. 
 
There is an association between the growing use of antimicrobial agents and an increase in the 
prevalence of microorganisms resistant to these agents. 
 
Antimicrobial resistance poses a threat to public health, may prolong the suffering of patients, 
increase healthcare costs, and has economic implications for society. 
 
To develop strategies for the prevention of infections and containment of resistant pathogens, 
accurate surveillance systems generating reliable data on incidence, prevalence and modes of 
spread of resistant microorganisms must be established [1, 4, 8, 10]. 
 
Microorganisms develop resistance through different mechanisms.  
 
One of the most widespread resistance mechanisms in microorganisms is their ability to 
produce destroying or modifying enzymes. The most known of them are β-lactamases. 
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β-lactamases comprise the major defence of gram-negative bacteria against β-lactam 
antibiotics. They hydrolyse the β-lactam ring of penicillins, cephalosporins and related drugs. 
There are dozens of β-lactamases, which vary in the substrate specificity and host range.  
These enzymes have evolved over decades of the β-lactam use and have developed the 
capability of targeting the growing number of antimicrobial compounds. 
 
After the introduction of broad-spectrum penicillins and early cephalosporins in 1960-1978, 
plasmids determining β-lactamases (e.g. TEM-1) disseminated among gram-negative bacilli. 
As a result, gram-negative bacilli acquired the capability to produce broad-spectrum   
β-lactamases. 
 
The clinical use of cephamycins, oxyimunocephalosporins, monobactams, carbapenems,   
β-lactamase inhibitors, led to the production of extended spectrum β-lactamases (ESBL) with 
an increased affinity for 3
rd generation cephalosporins and monobactams. It was the result of 
mutations in the plasmid genes TEM, SHV, OXA. Now there are approximately 50 different 
TEM mutants and 20 SHV β-lactamase mutants. ESBL are most prevalent in Klebsiella spp, 
but have also been described in many other Enterobacteriaceae [2, 4, 9, 11].  
 
The aim of the present study was to elucidate the frequency of ESBL producing strains among 
the representatives of the Enterobacteraceae family, isolated from hospitalised patients, and 
to evaluate their antimicrobial susceptibility.  
 
Materials and methods 
The study had been carried out in two hospitals in Riga – Infectology Centre of Latvia and 
children hospital “Gailezers” during 2005-2006. Identification of the isolated strains to the 
species level was performed in the mini API system; for antimicrobial susceptibility testing, 
we used the mini API system, agar disk diffusion test (BBL) according to CLSI standards and 
E-test (AB Biodisk) [5, 6, 12]. 
 
In order to detect ESBL production, we have systematically screened all Enterobacteriaceae 
strains isolated in our hospitals. We used the mini API ATB Expert system for screening. For 
confirmation, the following methods were applied: 
 
1)  a double-disk synergy test as suggested for Enterobacteriaceae [3]. We used cephtazidime 
disk 30 µg (CAZ), cephtazidime / clavulanate 30 / 10 µg (CAZ/CL) and cephotaxime 30 
µg (CTX), cephotaxime / clavulanate 30 / 10 µg (CTX/CL).  
 
2)  E-test. For E-test, cephtazidime / cephtazidime + clavulanate and cephotaxime / 
cehotaxime + clavulanate (AB Biodisk).  
 
Results and discussion 
A total of 507 strains, representatives of 8 genera of the Enterobacteraceae family, were 
isolated and tested for the production of ESBL. Positive results were registered in 
representatives of 3 genera – Escherichia, Klebsiella and Enterobacter. 
 
The most active ESBL production was documented in the Klebsiella genus: among K. 
pneumoniae strains, there were 36.65% ESBL producers, in K. oxytoca strains 38.8% (on the 
average, 37.7% for the genus). 
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Among the isolated E. coli strains, on the average, 5.95% were ESBL-producers (Table 1).  
 
The double-disk method confirmed 89.3% of ESBL production, from them CTX, CTX / CL – 
96.0%, CAZ, CAZ / CL – 56%.  
 
Using the E-test, 82.1% of positive results were confirmed, from them CT / CTL – 95.7%,  
TZ / TZL – 47.8%. 
 
Table 1 Production of ESBL among the representatives  
of the Enterobacteriaceae family during 1985-1986 in Latvia 
 
1985 1986 
ESBL producers  No. of ESBL  producers
Microorganisms 
No. of 
cultures  Abs. %  cultures  Abs. % 
E. coli  160 5  3.1  159  14  8.8 
K. pneumoniae  23 7  30.4  28  12  42.9 
K. oxytoca  17 7  41.2  11 4  36.4 
K. ornithinolytica  1 -  -  -  -  - 
E. cloacae  21 6  28.6  25 1  4.0 
E. aerogenes  1 -  -  6  -  - 
E. amniogenes  3 -  -  4  -  - 
E. sakazakii  1 -  -  4  -  - 
C. freundii  5  - -   -  - 
S. marcescens  3 -  -  6  -  - 
S. liquefaciens  1 -  -  1  -  - 
P. mirabilis  9 3  33.3  7 -  - 
P. vulgaris  2 -  -   -  - 
M. morganii  3 -  -  3  -  - 
Salmonella spp.  -  -  -  3  -  - 
 
In total: 
 
250 
 
28 
     
257 
 
31 
 
 
 
The antimicrobial susceptibility of the isolated strains was tested using the panel of 
antimicrobials. 
 
ESBL producing strains had the following characteristics: all strains of E. coli, Klebsiella and 
Proteus were susceptible to imipenem and clavulanate, E. coli to amikacin 100%, 
nitrofurantoin 92.3%, norfloxacin and ciprofloxacin 53.8%, cotrimoxazole 69.2%, gentamicin 
53.8% (Table 2).  
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Table 2 Susceptibility of broad-spectrum and extended-spectrum 
 β-lactamases (ESBL) producing E. coli strains to antimicrobials 
 
   
Susceptibility of E. coli strains (%) 
 
Antimicrobials  Production of broad 
spectrum β-lactamases 
Producers of ESBL 
Imipenem 100  100 
Clavulanate 100  100 
3
rd generation cephalosporins  100  - 
Amikacin 100  100 
Gentamicin 100  53.8 
Nitrofurantoin 96.3  92.3 
Norfloxacin 90.7  53.8 
Ciprofloxacin 91.5  53.8 
Cotrimoxazole 51.7  69.2 
 
Klebsiella strains were susceptible to amikacin 81.8%, norfloxacin and ciprofloxacin 54.5%, 
cotrimoxazole 45.5%, gentamicin 36.4%. 
 
In the present study, these data were compared with the results of investigating the 
susceptibilities of the strains, producing broad-spectrum β-lactamases. 
 
In this group, the results were different. 
 
All broad-spectrum β-lactamases producing E. coli,  Klebsiella and Proteus strains were 
susceptible to imipenem, clavulanate, 3rd generation cephalosporins, amikacin; E. coli - to 
gentamicin 100%, nitrofurantoin 96.3%, norfloxacin 90.7%, ciprofloxacin 91.5%, 
cotrimoxazole 51.7% (Table 2), Klebsiella to gentamicin, norfloxacin and ciprofloxacin 
94.4%, cotrimaxazole 77.8%, nitrofurantoin 72.2%. 
 
According to the polyresistance of ESBL-producing microbial strains, they are of crucial 
interest nowadays [1, 7, 8, 10, 11]. 
 
Extended-spectrum β-lactamases (ESBL) constitute a growing class of β-lactamases, which 
are often plasmid-mediated and are most commonly expressed in enterobacterial species. The 
majority of ESBLs are point mutant derivatives of the narrow-spectrum β-lactamases TEM-1, 
TEM-2 or SHV-1. They are Ambler class A β-lactamases, hydrolysing to different extents 
oxyiminocephalosporins, such as ceftriaxone, cefotaxime and ceftazidime, and monobactams 
such as aztreonam. The activity of these penicillinases remains inhibited by clavulanic acid. 
 
So, ESBL producing Enterobacteriaceae strains have acquired the resistance to all 
cephalosporins, penicillins and aztreonam. It is of great importance to implement ESBL 
detecting methods in clinical practice because Enterobacteriaceae may be incorrectly 
interpreted as susceptible to 3
rd and 4
th generation cephalosporins. The existing conventional 
susceptibility testing methods do not reveal all strains, producing ESBL. 
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Conclusions 
1.  The prevalence of ESBL producing E. coli is rather low – 5.95% and that of Klebsiella is 
high – 37.7%. 
2.  All ESBL producing strains are susceptible to imitenem and clavulanate, most of them to 
amikacin. The susceptibility to other antimicrobials varies from 36 to 92%. 
3.  For effective treatment of patients with 3
rd and 4
th generation cephalosporins, isolated 
Enterobacteriaceae strains should be tested for ESBL production. 
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